Dermatology Research
An Intervention Study for Adults with Moderate Plaque Psoriasis
This study is currently closed to enrollment.
Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy
AGE: 18 years and older
SEX AT BIRTH: All
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Plaque psoriasis
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center
LOCATION: UH Cleveland Medical Center
Study Purpose
The purpose of this study is to evaluate if the study drug, Risankizumab, is more effective to Apremilast in the treatment of moderate plaque psoriasis. The effectiveness of Risankizumab will be evaluated in subjects who have not been treated with Risankizumab and in subjects who switch from Apremilast to Risankizumab.